High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

Biological Psychiatry

Volumn 55, Issue 2, 2004, Pages 165-171

  Heresco Levy, Uriel ^a,d   Ermilov, Marina ^a   Lichtenberg, Pesah ^a   Bar, Gali ^a   Javitt, Daniel C ^b,c  

^a HEBREW UNIVERSITY   (Israel)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d HERZOG HOSPITAL   (Israel)

Author keywords

Glycine; NMDA receptor; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

AMINO ACID; ANTIPARKINSON AGENT; CHLORAL HYDRATE; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; TRIHEXYPHENIDYL; BENZODIAZEPINE DERIVATIVE; DRUG DERIVATIVE; PIRENZEPINE; SERINE;

ADULT; AGITATION; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INSOMNIA; LABORATORY DIAGNOSIS; MALE; NAUSEA; NEGATIVE SYNDROME; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; SYMPTOM; BEHAVIOR; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; TIME; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; BENZODIAZEPINES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PIRENZEPINE; RISPERIDONE; SCHIZOPHRENIA; SERINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 1442333154     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(03)00707-8     Document Type: Article

References (46)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed :1994;American Psychiatric Press, Washington, DC.
2. Azorin J.-M., Spiegel R., Remington G., Vanelle J.-M., Péré J.-J., Giguere M., et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry. 158:2001;1305-1313.
3. Barbeau A. Preliminary study of glycine administration in patients with spasticity. Neurology. 24:1974;392.
4. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4phenyl- tetrahydropyridine monkeys. J Pharmacol Exp Ther. 290:1999;1034-1040.
5. Bunney B.G., Bunney W.E. Jr, Carlsson A. Schizophrenia and glutamate. Bloom F.E., Kupfer D.J. Psychopharmacology: The Fourth Generation of Progress. 1995;1205-1214 Raven Press, New York.
6. Conley R.R., Tamminga C.A., Kelly D.L., Richardson C.M. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry. 46:1999;73-77.
7. Danysz W., Parsons C.G. Glycine and N-methyl-D-aspartate receptors Physiological significance and possible therapeutic applications. Pharmacol Rev. 50:1998;597-664.
8. Deutsch S.I., Mastropaolo J., Schwartz B.L., Rosse R.B., Morihisa J.M. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacology. 12:1989;1-13.
9. D'Souza C., Charney D., Krystal J. Glycine site agonists of the NMDA receptor A review. CNS Drug Reviews. 1:1995;227-260.
10. Evins A.E., Fitzgerald S.M., Wine L., Roselli R., Goff D.C. A placebo controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 157:2000;826-828.
11. Goff D.C., Henderson D.C., Evins Eden A., Amico D. A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 45:1999;512-514.
12. Goff D.C., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D.A., et al. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 56:1999;21-27.
13. Goff D.C., Tsai G., Manoach D.S., Coyle J.T. Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 152:1995;1213-1215.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology. 1995;U.S. Department of Health, Washington, DC.
15. Heresco-Levy U. Amino acid transmitter systems in schizophrenia and other psychotic disorders. D'haenen H., den Boer J.A., Willner P. Biological Psychiatry. 2002;587-600 John Wiley and Sons, London. Education and Welfare.
16. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Horowitz A., Kelly D. Double blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 169:1996;610-617.
17. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 56:1999;29-36.
18. Javitt D.C., Balla A., Sershen H., Lajtha A. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors. Biol Psychiatry. 45:1999;668-679.
19. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 148:1991;1301-1308.
20. Javitt D.C., Zylberman I., Zukin S.R., Heresco-Levy U., Lindenmayer J.P. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 151:1994;1234-1236.
21. Johnson J.W., Asher P. Glycine potentiates the NMDA responses in cultured mouse brain neurons. Nature. 325:1987;529-531.
22. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual. 1987;Social and Behavioral Sciences Documents, San Rafael, CA.
23. Kew J.N., Richards J.G., Mutel V., Kemp J.A. Developmental changes in NMDA receptor glycine affinity and ifenprodil sensitivity reveal three distinct populations of NMDA receptors in individual rat cortical neurons. J Neurosci. 18:1998;1935-1943.
24. Kleckner N.W., Dingledine R. Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science. 241:1988;835-837.
25. Korpi E.R., Kaufman C.A., Marnela K.M., Weinberger D.R. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res. 20:1987;337-345.
26. Kostakow S., Slanck A. Glycocoll treatment of progressive muscular dystrophy. Deutsch Arch Klin Med. 175:1933;25-37.
27. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry. 51:1994;199-214.
28. Lahti A.C., Koffel B., Laporte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacol. 13:1995;9-19.
29. Leiderman E., Zylberman I., Zukin S.R., Cooper T.B., Javitt D.C. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia An open label trial. Biol Psychiatry. 39:1996;213-215.
30. Lindenmayer J.P., Bernstein-Hyman R., Grochowski S. Five-factor model of schizophrenia Initial validation. J Nerv Ment Dis. 182:1994;631-638.
31. Luby E.D., Cohen B.D., Rosenbaum F., Gottlieb J., Kelley R. Study of a new schizophrenomimetic drug, Sernyl. Arch Neur Psychiatry. 81:1959;363-369.
32. Malhotra A.K., Pinals D.A., Adler C.M., Elman I., Clifton A., Pickar D., et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacol. 17:1997;141-150.
33. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., et al. NMDA receptor function and human cognition The effects of ketamine in healthy volunteers. Neuropsychopharmacol. 14:1996;301-307.
34. Milhorat A.T. Treatment of progressive muscular dystrophy and similar muscular disturbances with glycine. Deutsch Arch Klin Med. 174:1933;487-517.
35. Nikam S.S., Meltzer L.T. NR2B selection NMDA receptor antagonists. Curr Pharm Des. 8:2002;845-855.
36. Overall J.E., Gorham D.E. The Brief Psychiatric Rating Scale. Psychol Rep. 10:1961;799-812.
37. Potkin S.G., Jin Y., Bunney B.G., Costa J., Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry. 156:1999;145-147.
38. Rosse R.B., Thuet S.K., Banay-Schwartz M., Leighton M., Scarcella E., Cohen C.G., et al. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia An open-label pilot study. Clin Neuropharmacol. 12:1989;416-424.
39. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scand Suppl. 212:1970;11-19.
40. Stern P., Bokonjic R. Glycine therapy in 7 cases of spasticity. Pharmacol. 12:1974;117-119.
41. Tamminga C.A. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol. 12:1998;37-67.
42. Toth E., Lajtha A. Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res. 11:1986;393-400.
43. Tsai G., Passani L.A., Slusher B.S., Carter L., Baer L., Kleinman Y.E., et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry. 52:1995;829-836.
44. Tsai G.E., Pinchen Yang L., Chung L., Tsai I., Tsai C., Coyle J.T. d-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 156:1999;1822-1825.
45. Tsai G., Yong P., Chung L.-C., Lange N., Coyle J.T. d-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 44:1998;1081-1089.
46. Wirshing D.A., Marshall B.D. Jr, Green M.F., Mintz J., Marder S.R., Wirshing W.C. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry. 156:1999;1374-1379.